3
Shared Docs
3
Same-Page
3 / 4
Mentions
DL cholesterol," says Steven Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising." But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager."If these drugs are used as broadly as they could be used, they are
ainst heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost down the line. "Obvi
low me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being ad
T_025888 --- PAGE BREAK --- Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are g
Page: HOUSE_OVERSIGHT_025889 →had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w
Page: HOUSE_OVERSIGHT_025889 →LDL cholesterol,” says Steven Nissen, chairman of cardiology at the Cleveland Clinic. “It’s very promising.” But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager.“If these drugs are used as broadly as they could be used, they are g
Page: HOUSE_OVERSIGHT_026363 →had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It’s likely that insurance companies w
Page: HOUSE_OVERSIGHT_026363 →Entities connected to both Troy Brennan and Praluent

Jeffrey Epstein
PERSON
Amgen
ORGANIZATION
John Brennan
PERSONRegeneron
PERSONTarrytown
LOCATION
the Cleveland Clinic
ORGANIZATION
Matthew Herper
PERSONNissen
PERSONLeonard S. Schleifer
PERSON
Mark Schoenebaum
PERSON
Geoffrey Porges
PERSONSchleifer
PERSON
Olivier Brandicourt
PERSON
CVS Caremark
ORGANIZATION
Pfizer
ORGANIZATION
Sanford C. Bernstein
ORGANIZATION
Donald Trump
PERSONSultan Bin Sulayern
PERSONthe Human Genome
ORGANIZATIONVioxx
ORGANIZATION